Time-restricted feeding exacerbates liver fibrosis by promoting BDH1-mediated ketolysis in hepatic stellate cells.

This study reveals that time-restricted feeding exacerbates liver fibrosis by elevating systemic ketone bodies, which hepatic stellate cells metabolize via BDH1-mediated ketolysis to fuel a profibrogenic metabolic state.

The Gist

Imagine your liver is a busy city. When this city gets injured (by toxins, bad diet, or blocked pipes), it sends out a repair crew called Hepatic Stellate Cells (HSCs). Normally, these workers are like construction managers who lay down temporary scaffolding to fix the damage. But if the injury keeps happening, these workers get stuck in "overdrive." They stop fixing and start building too much permanent concrete (scar tissue), turning the flexible city into a rigid, crumbling ruin. This is liver fibrosis.

For years, scientists have thought that Time-Restricted Feeding (TRF)—eating only within a specific window of the day (like an 8-hour window) and fasting the rest—was like a "city-wide power-down" that helped the liver rest and heal. It's a popular diet trend for metabolic health.

But this paper flips the script. It suggests that for a liver already under attack and building scars, this "power-down" might actually be making things worse.

Here is the story of how that happens, broken down into simple steps:

1. The "Emergency Fuel" Mix-Up

When you fast (like during TRF), your body runs out of its usual fuel (sugar) and switches to a backup generator. This generator burns fat and produces Ketone Bodies (specifically a chemical called BHB).

• The Analogy: Think of BHB as "emergency diesel fuel." For a healthy body, this is great; it keeps the lights on when the main power grid is off.
• The Problem: In a liver that is already trying to build scars, this emergency fuel isn't just sitting there. It's being delivered straight to the overworked construction crews (the HSCs).

2. The Construction Crew's Secret Weapon: BDH1

Inside these scar-building cells, there is a special machine called BDH1.

• The Analogy: Imagine the construction crew has a special adapter plug (BDH1) that allows them to plug directly into the "emergency diesel" (BHB) and turn it into pure energy and building materials.
• What Happens: When TRF floods the system with BHB, the BDH1 machine in the scar-cells goes into overdrive. It takes that fuel and converts it into Acetyl-CoA and Citrate.
• The Result: These chemicals are the raw ingredients for making new fats and energy. Instead of using this energy to rest, the scar-cells use it to build even more concrete (collagen). The more fuel they get, the faster they build the scar tissue.

3. The Experiment: Proving the Theory

The researchers tested this in mice with three different types of liver damage.

• The Setup: They put some mice on a normal eating schedule and others on the Time-Restricted Feeding diet.
• The Shock: The mice on the diet didn't get better; their livers got more scarred. The "emergency fuel" (BHB) was high, and the scar-cells were working overtime.
• The Sabotage:
  • Cutting the Fuel: When they stopped the liver from making the emergency fuel (BHB), the diet no longer made the scars worse.
  • Adding the Fuel: When they gave mice extra BHB (without the diet), their livers got scarred just as badly as the diet group.
  • Breaking the Machine: When they genetically removed the BDH1 adapter from the scar-cells, the diet stopped hurting them. The scar-cells couldn't use the emergency fuel anymore, so they slowed down their construction.

The Big Takeaway

This study is a warning label for a specific group of people.

If you have a healthy liver, Time-Restricted Feeding might be a great way to reset your metabolism. But if you already have chronic liver disease or active scarring (fibrosis), this diet might be like pouring gasoline on a fire.

The "fasting" state creates a flood of emergency fuel (ketones) that the damaged liver's scar-cells hijack to build more scars. The researchers suggest that people with active liver fibrosis should be very careful with diets that force the body into deep ketosis (like strict fasting or keto diets) until we know more.

In short: For a liver in crisis, the "emergency fuel" meant to save it is actually feeding the very thing destroying it.

Technical Summary

1. Problem Statement

Time-restricted feeding (TRF) is widely recognized as a beneficial dietary intervention for metabolic health, improving insulin sensitivity and reducing inflammation. However, its impact on the progression of chronic liver disease, specifically liver fibrosis, remains poorly defined. While TRF may alleviate metabolic dysfunction-associated steatohepatitis (MASH), there is a lack of understanding regarding whether the metabolic shifts induced by TRF (such as ketosis) could be detrimental in the context of established liver injury. The study aims to investigate if TRF exacerbates liver fibrogenesis and to elucidate the underlying molecular and metabolic mechanisms.

2. Methodology

The researchers employed a multi-faceted approach combining in vivo murine models, in vitro cell culture, and metabolic tracing:

• Animal Models: Three distinct murine models of liver fibrosis were utilized to ensure robustness:
  1. CCl₄-induced: Toxin-induced fibrosis.
  2. BDL-induced: Bile duct ligation (cholestatic) fibrosis.
  3. CDAHFD-induced: Choline-deficient, L-amino acid-defined high-fat diet (metabolic) fibrosis.
  • Intervention: Mice were subjected to either ad libitum feeding (Control) or a Time-Restricted Feeding (TRF) regimen.
• Genetic Manipulation:
  • Hepatic Ketogenesis Inhibition: Adeno-associated virus (AAV) vectors were used to knockdown Hmgcs2 (the rate-limiting enzyme for ketogenesis) specifically in the liver to prevent TRF-induced hyperketonemia.
  • HSC-Specific Gene Ablation: Mice with a conditional knockout of Bdh1 (3-hydroxybutyrate dehydrogenase 1) specifically in hepatic stellate cells (HSCs) using Lrat-Cre (Bdh1^f/f; Lrat-Cre) were generated.
• Pharmacological Interventions: Exogenous administration of sodium β-hydroxybutyrate (BHB) to mimic the ketotic state.
• In Vitro Studies: Primary mouse and human HSCs (including LX2 cell line) were treated with BHB.
• Metabolic Tracing: Stable isotope tracing using [U-¹³C]BHB and [U-¹³C]glucose in primary human HSCs to track carbon flux into the TCA cycle and lipogenesis.
• Readouts: Histology (Masson's trichrome, Sirius Red), biochemical assays (hydroxyproline content), qRT-PCR (α-SMA, Bdh1), Western blotting, and plasma metabolite analysis.

3. Key Contributions

• Paradigm Shift on TRF: The study challenges the notion that TRF is universally beneficial for liver health, demonstrating that in the context of active liver injury, it exacerbates fibrosis.
• Identification of a Novel Mechanism: The authors identified BDH1-mediated ketolysis in hepatic stellate cells (HSCs) as the critical driver of this detrimental effect.
• Metabolic Reprogramming: The paper elucidates how systemic ketone bodies (BHB) are metabolized by activated HSCs to fuel de novo lipogenesis (DNL) via the TCA cycle, providing the metabolic substrates necessary for fibrogenesis.
• Therapeutic Target: The study validates BDH1 in HSCs as a potential therapeutic target to mitigate fibrosis exacerbated by ketogenic dietary patterns.

4. Key Results

A. TRF Exacerbates Liver Fibrosis

Across all three murine models (CCl₄, BDL, CDAHFD), TRF consistently worsened liver fibrosis compared to ad libitum feeding.

• Evidence: Significant increases in collagen deposition (Masson's trichrome area), hepatic hydroxyproline content, and mRNA expression of the activated HSC marker α-SMA.
• Note: TRF did not significantly alter liver injury markers (ALT/AST), suggesting the effect is specific to fibrogenesis rather than acute hepatocellular necrosis.

B. The Role of Ketone Bodies (BHB)

• Hyperketonemia: TRF induced a significant systemic elevation of β-hydroxybutyrate (BHB) in all fibrotic models.
• Causality:
  • Knockdown of Hmgcs2: Preventing hepatic ketogenesis abolished the TRF-induced rise in plasma BHB and subsequently mitigated the exacerbation of fibrosis.
  • Exogenous BHB: Administering BHB alone to fibrotic mice (without TRF) was sufficient to recapitulate the exacerbated fibrotic phenotype (increased collagen and α-SMA).
  • In Vitro: BHB directly stimulated pro-collagen I production and synergized with TGF-β to upregulate α-SMA in HSCs.

C. BDH1 as the Critical Mediator in HSCs

• Upregulation: Activated HSCs in fibrotic livers showed marked upregulation of BDH1, the enzyme responsible for ketolysis (converting BHB to acetoacetate/acetyl-CoA).
• Metabolic Flux: Isotope tracing revealed that BDH1-mediated ketolysis redirects BHB-derived carbons into the TCA cycle, generating citrate and acetyl-CoA. These metabolites are exported to the cytosol to fuel de novo lipogenesis (DNL), supporting the high energy and biosynthetic demands of activated HSCs.
• Genetic Ablation:
  • In Vitro: HSCs lacking Bdh1 were completely resistant to BHB-induced collagen production and α-SMA upregulation.
  • In Vivo: HSC-specific knockout of Bdh1 (Bdh1^f/f; Lrat-Cre) protected mice from the pro-fibrotic effects of both TRF and exogenous BHB administration.

5. Significance and Conclusion

This study reveals a context-dependent detrimental role for Time-Restricted Feeding in patients with chronic liver injury. While TRF may benefit metabolic health in healthy individuals or early-stage steatosis, it drives fibrosis progression in injured livers by elevating systemic ketone bodies.

The mechanism involves a specific metabolic reprogramming in hepatic stellate cells:

1. TRF $\rightarrow$ Systemic Hyperketonemia (High BHB).
2. Activated HSCs upregulate BDH1.
3. BDH1 converts BHB into Acetyl-CoA/Citrate.
4. These metabolites fuel lipogenesis and the TCA cycle, providing the energy and building blocks for HSC activation and ECM deposition.

Clinical Implication: Dietary interventions that induce ketosis (such as TRF, ketogenic diets, or prolonged fasting) should be approached with extreme caution in patients with active liver fibrosis. Targeting the BDH1 pathway in HSCs represents a promising therapeutic strategy to block the metabolic fuel supply required for fibrotic progression.

Limitations: The study is primarily preclinical (murine models), and the kinetics of TRF-induced ketosis in human fibrotic cohorts require further validation. Additionally, interactions between BHB-stimulated HSCs and other non-parenchymal liver cells warrant further investigation.